07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MLX interacting protein (MLXIP); thioredoxin interacting protein (TXNIP); arrestin domain containing 4 (ARRDC4)

Endocrine/metabolic disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting the MLXIP/TXNIP/ARRDC4 pathway could help treat obesity. In cultured human skeletal myotubes, siRNA targeting MLXIP or a MLXIP inhibitor tool compound increased insulin-stimulated glucose uptake and...